Proteasomal turnover of p21Cip1 does not require p21Cip1 ubiquitination - PubMed (original) (raw)
Proteasomal turnover of p21Cip1 does not require p21Cip1 ubiquitination
R J Sheaff et al. Mol Cell. 2000 Feb.
Free article
Abstract
The Cdk inhibitor p21Cip1 is an unstable protein. Pharmacologic inhibition of the proteasome increases the half-life of p21 from less than 30 min to more than 2 hr and results in the accumulation of p21-ubiquitin conjugates. To determine whether ubiquitination was required for proteasomal degradation of p21, we constructed mutant versions of p21 that were not ubiquitinated in vivo. Remarkably, these mutants remained unstable and increased in abundance upon proteasome inhibition, indicating that direct ubiquitination of p21 is not necessary for its turnover by the proteasome. The frequently observed correlation between protein ubiquitination and proteasomal degradation is insufficient to conclude that ubiquitination is a prerequisite for degradation.
Similar articles
- To be or not to be ubiquitinated?
Bloom J, Pagano M. Bloom J, et al. Cell Cycle. 2004 Feb;3(2):138-40. Cell Cycle. 2004. PMID: 14712075 Review. - Growth inhibition by CDK-cyclin and PCNA binding domains of p21 occurs by distinct mechanisms and is regulated by ubiquitin-proteasome pathway.
Rousseau D, Cannella D, Boulaire J, Fitzgerald P, Fotedar A, Fotedar R. Rousseau D, et al. Oncogene. 1999 May 27;18(21):3290-302. doi: 10.1038/sj.onc.1202681. Oncogene. 1999. PMID: 10359535 - Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway.
Diehl JA, Zindy F, Sherr CJ. Diehl JA, et al. Genes Dev. 1997 Apr 15;11(8):957-72. doi: 10.1101/gad.11.8.957. Genes Dev. 1997. PMID: 9136925 - Growth inhibition by CDK-cyclin and PCNA binding domains of p21 occurs by distinct mechanisms and is regulated by ubiquitin-proteasome pathway.
Rousseau D, Cannella D, Boulaire J, Fitzgerald P, Fotedar A, Fotedar R. Rousseau D, et al. Oncogene. 1999 Jul 29;18(30):4313-25. doi: 10.1038/sj.onc.1202686. Oncogene. 1999. PMID: 10439039 - Ubiquitination and deubiquitination: targeting of proteins for degradation by the proteasome.
Wilkinson KD. Wilkinson KD. Semin Cell Dev Biol. 2000 Jun;11(3):141-8. doi: 10.1006/scdb.2000.0164. Semin Cell Dev Biol. 2000. PMID: 10906270 Review.
Cited by
- Tuning the proteasome to brighten the end of the journey.
Mayor T, Sharon M, Glickman MH. Mayor T, et al. Am J Physiol Cell Physiol. 2016 Nov 1;311(5):C793-C804. doi: 10.1152/ajpcell.00198.2016. Epub 2016 Sep 7. Am J Physiol Cell Physiol. 2016. PMID: 27605452 Free PMC article. Review. - Cellular proteasome activity facilitates herpes simplex virus entry at a postpenetration step.
Delboy MG, Roller DG, Nicola AV. Delboy MG, et al. J Virol. 2008 Apr;82(7):3381-90. doi: 10.1128/JVI.02296-07. Epub 2008 Jan 30. J Virol. 2008. PMID: 18234803 Free PMC article. - Two-Step Mechanism of Cyclin B Degradation Initiated by Proteolytic Cleavage with the 26 S Proteasome in Fish.
Tokumoto T, Hossain MF, Jyoti MMS, Ali MH, Hossain MB, Acharjee M, Rezanujjaman M, Tokumoto M. Tokumoto T, et al. Sci Rep. 2020 Jun 2;10(1):8924. doi: 10.1038/s41598-020-65009-w. Sci Rep. 2020. PMID: 32488101 Free PMC article. - Inhibition of proteasome deubiquitinating activity as a new cancer therapy.
D'Arcy P, Brnjic S, Olofsson MH, Fryknäs M, Lindsten K, De Cesare M, Perego P, Sadeghi B, Hassan M, Larsson R, Linder S. D'Arcy P, et al. Nat Med. 2011 Nov 6;17(12):1636-40. doi: 10.1038/nm.2536. Nat Med. 2011. PMID: 22057347 - A ubiquitin-proteasome pathway for the repair of topoisomerase I-DNA covalent complexes.
Lin CP, Ban Y, Lyu YL, Desai SD, Liu LF. Lin CP, et al. J Biol Chem. 2008 Jul 25;283(30):21074-83. doi: 10.1074/jbc.M803493200. Epub 2008 May 30. J Biol Chem. 2008. PMID: 18515798 Free PMC article.